Clinical trials: Kidney Donor
Kidney Transplant; Complications, Delayed Graft Function
Study of the Correlation Between Donor CIRBP and Transplanted Kidney Function
Deceased donors and recipients who successfully completed kidney transplantation between 2016 and 2019 were included in this study.
- Trial name
- NCT06641622
- Testing
- Prediction of delayed graft function
- Where
- China
- Volunteers
- 207 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Kidney Transplantation
Impact of HLA Evolutionary Divergence and HLA Donor-recipient Molecular Mismatches on Kidney Allograft Rejection
The Human Leucocyte Antigen (HLA) system is pivotal in kidney transplant rejection. In-silico methods such as HLA eplet mismatches and PIRCHE-II scores have emerged to refine HLA immunogenicity assessment and stratify patients…
- Trial name
- NCT06436586
- Testing
- No intervention
- Where
- France
- Volunteers
- 5,159 people, healthy volunteers welcome
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Renal Transplant Rejection
The Effect of Rituximab on the Development of Anti-Donor Antibodies
The aim of the study is to find out if Rituximab, which is an antibody against specific white cells involved in rejection, when combined with standard anti-rejection treatment can more effectively reverse the rejection process.
- Trial name
- NCT00695097
- Testing
- Rituximab, No Rituximab
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of California, San Francisco
Delayed Graft Function, Kidney Transplantation
Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation
The purpose of this study is to evaluate the efficacy of Eculizumab in the prevention of Delayed Graft Function following deceased donor kidney transplantation.
- Conditions
- Delayed Graft Function, Kidney Transplantation, Complement Activity
- Trial name
- NCT01919346
- Testing
- Eculizumab, Normal Saline
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Heeger, Peter, M.D.
Kidney Function Test
Development of a Bayesian Estimator for Calculating Plasma Iohexol Clearance
In kidney transplantation, donor selection is based in part on the assessment of the functional capacity of the kidneys. For this purpose, it is recommended to measure the glomerular filtration rate (GFR) by a reference…
- Trial name
- CLIO (NCT05136963)
- Testing
- Iohexol, pharmacokinetics
- Where
- France
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Kidney Tansplant, Acute Rejection (AR) of Transplanted Kidney
Daratumumab for Late Antibody-Mediated Rejection
The study titled "Daratumumab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients with De Novo Donor-Specific Antibodies" (DARTABMR) is a case-control investigation assessing whether daratumumab is more effective…
- Trial name
- DARTABMR (NCT07081126)
- Testing
- Daratumumab (Subcutaneously), control group
- Where
- Slovakia
- Volunteers
- 20 people
- Sponsor
- University Hospital, Martin
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
This clinical trial studies fludarabine phosphate, low-dose total body irradiation, and donor stem cell transplant in treating patients with hematologic malignancies or kidney cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00005799
- Testing
- fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- 7 sites in United States, Germany
- Volunteers
- 55 people
- Sponsor
- Fred Hutchinson Cancer Center
Renal Cell Carcinoma, Graft-Versus-Host Disease
Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer
Background: Low-dose chemotherapy is easier for the body to tolerate than typical high-dose chemotherapy and involves a shorter period of complete immune suppression.
- Conditions
- Renal Cell Carcinoma, Graft-Versus-Host Disease, Engraftment Syndrome
- Trial name
- NCT00923845
- Testing
- Pentostatin, Sirolimus, Cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Failure, Kidney Transplant
Worldwide Assessment of Deceased Donor Kidney Utilization
The persistent imbalance between kidney transplant demand and organ availability remains a major global challenge. Optimizing the utilization of kidneys from deceased donors is a critical strategy to expand the donor pool and…
- Conditions
- Kidney Failure, Kidney Transplant, Deceased Donor Kidney Transplant
- Trial name
- NCT07341516
- Where
- 2 sites in United States, France
- Volunteers
- 300,000 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Kidney Cancer
Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00243009
- Testing
- cyclosporine, fludarabine phosphate, mycophenolate mofetil
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- OHSU Knight Cancer Institute
Kidney Transplant; Complications, Muscle Relaxation
Progressive Relaxation Exercises for Kidney Donors
Complex emotions and other possible changes associated with agreeing to enroll after laparoscopic donor nephrectomy may cause living donors to experience anxiety, increase in perceived pain temperature, or last longer after…
- Trial name
- NCT06394245
- Testing
- Progressive muscle exercises
- Volunteers
- 63 people
- Sponsor
- Fenerbahce University
Kidney Transplant
Clinical Study on Thymus-Kidney Transplantation From Neonatal Donors for the Induction of Immune Tolerance
Thymus transplantation for the induction of immune tolerance in kidney transplantation: This study aims to understand how thymus transplantation can induce immune tolerance in recipients of allogeneic kidney transplants to…
- Trial name
- NCT06715865
- Testing
- Thymus Transplantation
- Where
- China
- Volunteers
- 10 people
- Sponsor
- RenJi Hospital
Kidney Transplant Rejection
Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transplants
The Phase 2 primary objective is to evaluate achievement of persistent mixed chimerism and withdrawal of at least one immunosuppression drug for a minimum of 6 months with no episodes of biopsy-proven acute rejection or…
- Trial name
- NCT03605654
- Testing
- MDR-102, Immunosuppressive Agents
- Sponsor
- Medeor Therapeutics, Inc.
Chronic Kidney Disease, End Stage Renal Disease
Educating Missouri Patients About Preemptive Living Donor Transplantation
This study is a group-randomized controlled trial to explore whether improved community transplant education for renal patients not yet on dialysis could increase patients' willingness to pursue preemptive living donor transplant…
- Trial name
- NCT01048437
- Testing
- Transplant education with video, Transplant education with speakers
- Where
- 5 sites in United States
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Kidney Transplantation
Alefacept in Kidney Transplant Recipients
Alefacept, also known as Amevive®, is a medication approved by the Food and Drug Administration (FDA) in the United States and other countries for the treatment of psoriasis, which is a chronic inflammatory immunological skin…
- Trial name
- NCT01433770
- Testing
- Amevive
- Where
- United States
- Sponsor
- University Hospitals Cleveland Medical Center
Kidney Disease
Donor-Alloantigen-Reactive Regulatory T Cell (darTreg) Therapy in Renal Transplantation (The ONE Study )
This Phase I pilot study will evaluate the safety, and tolerability of darTreg infusion for adult, de novo, living donor renal transplant recipients.
- Trial name
- DART (NCT02244801)
- Testing
- darTreg infusion
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Francisco
Kidney Transplant Failure and Rejection, Kidney Transplant; Complications
ECP-DL Cell Infusion for Induction in Living Donor Kidney (LDK) Transplants
This is a phase 1 trial, 36 month duration for subjects with end-stage renal disease (ESRD). The objectives of the trail are1) Determine the safety of ECP-DL cell infusion in living donor renal transplant recipients.
- Trial name
- ECP (NCT07083830)
- Testing
- ECP-DL treated mononuclear cell infusion
- Volunteers
- 24 people
- Sponsor
- Northwestern University
Living-Kidney Donors
Dietary Interventions During Living Kidney Donations
Monocentre, non-randomized, non-blinded, open-label interventional study to identification of relevant changes in molecular biology in proteome, phosphoproteome, lipidome, epigenome and transcriptome in pretransplant kidney…
- Trial name
- DILKID (NCT05709600)
- Testing
- Fasting mimicking diet, Ketogenic diet, Dietary restriction of sulfur containing amino acids
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Cologne
Renal Transplantation
Study Evaluating The Use Of Sirolimus In Recipients Of Kidney Allografts From Expanded Criteria Donors (ECD)
The purpose of this observational study is to examine the clinical outcomes of the use of sirolimus as base therapy in kidney allograft recipients from Expanded Criteria Donors (ECD) under conditions of routine clinical practice.
- Trial name
- NCT00697112
- Testing
- Sirolimus
- Where
- 8 sites in Argentina
- Volunteers
- 53 people
- Sponsor
- Pfizer
Kidney Transplant
The Paired Donation Consortium Paired Donation Program
The purpose of the protocol is to increase the number of living donor transplants by eliminating immune incompatibilities between donors and recipients through paired donation.
- Trial name
- NCT00374400
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Cincinnati